title: Comparison of the EORTC QLQ-BN20 and the FACT-Br quality  of life questionnaires for patients with primary brain cancers:  a literature review.
abstract: OBJECTIVE
  This review compares and contrasts the development, validity, and characteristics of two quality of life (QOL) assessment tools used in patients with primary brain cancers: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Brain Cancer Module (EORTC QLQ-BN20) and the Functional Assessment of Cancer Therapy-Brain (FACT-Br).
  
  
  METHODS
  A literature search was conducted using the Cochrane Central Register of Controlled Trials (June 2013), Ovid EMBASE (1947 to 2013, week 27), and Ovid MEDLINE (1946 to July 2013, week 1) to identify studies that discussed the development, characteristics, validity, and reliability of the EORTC QLQ-BN20 or the FACT-Br.
  
  
  RESULTS
  The EORTC QLQ-BN20 consists of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit. Items are presented as questions on a scale ranging from 1 = “not at all” to 4 = “very much.” Reliability and validity testing of the QLQ-BN20 revealed a Cronbach’s alpha coefficient that ranged from 0.71 to 0.90. The FACT-Br consists of 23 items that assess general well-being and brain cancer-specific concerns that include concentration, memory, seizures, eyesight, hearing, speech, personality, expression of thoughts, weakness, coordination, and headaches. These items are presented as statements on a scale ranging from 0 = “not applicable” to 4 = “extremely relevant.” The FACT-Br underwent validity as well as test-retest reliability testing with 101 and 46 patients, respectively. Validity testing found low to moderate correlation with the FACT-G questionnaire, while reliability testing for the brain subscale revealed an acceptable correlation coefficient (r = 0.66; p < 0.001).
  
  
  CONCLUSIONS
  The QLQ-BN20 and the FACT-Br are both valid and reliable tools that have been used extensively in the primary brain cancer population. Choice between the two tools should consider each instrument’s individual strengths and weaknesses.
authors.forename: Ronald
authors.initials: R
authors.lastname: Chow
authors.forename: Nicholas
authors.initials: N
authors.lastname: Lao
authors.forename: Marko
authors.initials: M
authors.lastname: Popovic
authors.forename: Edward
authors.initials: E
authors.lastname: Chow
authors.forename: David
authors.initials: D
authors.lastname: Cella
authors.forename: Jennifer
authors.initials: J
authors.lastname: Beaumont
authors.forename: Henry
authors.initials: H
authors.lastname: Lam
authors.forename: Natalie
authors.initials: N
authors.lastname: Pulenzas
authors.forename: Gillian
authors.initials: G
authors.lastname: Bedard
authors.forename: Erin
authors.initials: E
authors.lastname: Wong
authors.forename: Carlo
authors.initials: C
authors.lastname: DeAngelis
authors.forename: Andrew
authors.initials: A
authors.lastname: Bottomley
mesh_terms: D001932:Brain Neoplasms / Q000523:psychology / Q000628:therapy*; D003142:Communication; D006801:Humans; D011594:Psychometrics / Q000379:methods; D011788:Quality of Life; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires